Athira Pharma, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
LONA$4.02-10.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
For the Three and Six Months Ended June 30, 2025 and 2024
(in thousands, except share amounts)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-In · OtherComprehensive · Accumulated · TotalStockholders’ | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of January 1, 2025 | 39,040,945 | $4 | $450,982 | $1 | $(406,146) | $44,841 |
| Issuance of common stock upon vesting of restricted stock units | 1,500 | — | — | — | — | — |
| Stock-based compensation | — | — | 1,637 | — | — | 1,637 |
| Unrealized loss on available-for-sale securities | — | — | — | (5) | — | (5) |
| Net loss | — | — | — | — | (9,143) | (9,143) |
| Balance as of March 31, 2025 | 39,042,445 | $4 | $452,619 | $(4) | $(415,289) | $37,330 |
| Issuance of common stock upon vesting of restricted stock units | 296,880 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 100,001 | — | 24 | — | — | 24 |
| Stock-based compensation | — | — | 1,597 | — | — | 1,597 |
| Unrealized loss on available-for-sale securities | — | — | — | 1 | — | 1 |
| Net loss | — | — | — | — | (6,966) | (6,966) |
| Balance as of June 30, 2025 | 39,439,326 | $4 | $454,240 | $(3) | $(422,255) | $31,986 |
| Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-In · OtherComprehensive · Accumulated · TotalStockholders’ | ||||||||
| Shares · Amount · Capital · Income (Loss) · Deficit · Equity | ||||||||
| Balance as of January 1, 2024 | 38,172,603 | $4 | $439,739 | $(349) | $(309,206) | $130,188 | ||
| Issuance of common stock upon vesting of restricted stock units | 154,049 | — | — | — | — | — | ||
| Stock-based compensation | — | — | 2,679 | — | — | 2,679 | ||
| Unrealized gain on available-for-sale securities | — | — | — | 212 | — | 212 | ||
| Net loss | — | — | — | — | (26,337) | (26,337) | ||
| Balance as of March 31, 2024 | 38,326,652 | $4 | $442,418 | $(137) | $(335,543) | $106,742 | ||
| Issuance of common stock upon vesting of restricted stock units | 2,000 | — | — | — | — | — | ||
| Issuance of common stock under employee stock purchase plan | 110,723 | — | 148 | — | — | 148 | ||
| Stock-based compensation | — | — | 3,205 | 3,205 | ||||
| Unrealized gain on available-for-sale securities | — | — | — | 99 | 99 | |||
| Net loss | — | — | — | — | (26,859) | (26,859) | ||
| Balance as of June 30, 2024 | 38,439,375 | $4 | $445,771 | $(38) | $(362,402) | $83,335 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.